12:00 AM
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Humira adalimumab regulatory update

EMA's CHMP issued a positive opinion to expand the label of Humira adalimumab from Abbott to include treatment of moderately to severely active Crohn's disease in adult patients who have not responded despite...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >